Celltrion | 068270 - Selling And Administration Expenses


Celltrion reported KRW12.71B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Celltrion KRW 12.71B 237.27B Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Moderna USD 173M 135M Mar/2026
Organon & Co USD 433M 34M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025